June 2019

Prostate cancer (PCa) is one of the most common cancers and one of the leading causes of death worldwide. Thus, one major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. In this study, we aim to validate the usefulness of diagnostic nomograms (DN) to detect csPCa, based on previously published urinary biomarkers.

Mosaiques’ diagnostics study entitled:

“CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer”

was awarded in 13. Nordkongress Urologie in Hamburg

13 – 15 June 2019

The study presents a CE-MS based urinary test of 19-peptides that enables detection of significant prostate cancer in patients with low levels of PSA (<15ng/ml) with sensitivity of 90% (AUC=0.81), outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69)

Please find more information on the Study:
https://www.ncbi.nlm.nih.gov/pubmed/31092909